SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVE
The frequency of hypertriglyceridemia is high in CKD patients, but few medications are available for controlling this lipid parameter when renal insufficiency advances. We evaluated the safety and efficacy of long-term treatment with rosuvastatin, one of the strong statins for hypercholesterolemic c...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Nephrology
2012-06-01
|
Series: | Kidney Research and Clinical Practice |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211913212006328 |
id |
doaj-4121cdafe99b466395ec834fe3406f85 |
---|---|
record_format |
Article |
spelling |
doaj-4121cdafe99b466395ec834fe3406f852020-11-24T21:10:28ZengThe Korean Society of NephrologyKidney Research and Clinical Practice2211-91322012-06-01312A8610.1016/j.krcp.2012.04.599SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVEJun YutoYosuke EharaKazuhiko ShibataTamio IwamotoGen YasudaMari KatsumataYuichiro YamamotoNobuhito HirawaThe frequency of hypertriglyceridemia is high in CKD patients, but few medications are available for controlling this lipid parameter when renal insufficiency advances. We evaluated the safety and efficacy of long-term treatment with rosuvastatin, one of the strong statins for hypercholesterolemic control, on lipid abnormalities in patients with CKD stage 3 and above. The protocol consisted of a 4-week run-in period and a 48-week treatment phase with rosuvastatin. Inclusion criteria were CKD stage 3 and above with serum low-density lipoprotein (LDL) cholesterol levels above 100 mg/dL and triglyceride levels above 150 mg/dL. Patients received 2.5 to 5.0 mg rosuvastatin daily. Lipid parameters and myolysis-related indicators were measured. Forty-nine patients (29 men and 20 women aged 61 ± 9 years, serum creatinine levels above 1.5 mg/dL) were enrolled in the study. Rosuvastatin significantly decreased (P〈0.05) serum LDL cholesterol from 163 ± 39 to 126 ± 31 mg/dL and apolipoprotein B from 151 ± 36 to 108 ± 24 mg/dL at 4 weeks and maintained these parameters at low levels. Rosuvastatin also significantly decreased (P = 0.001) serum triglyceride levels from 194 ± 43 mg/dL at baseline to 160 ± 51 mg/dL at 48 weeks. High-density lipoprotein (HDL) cholesterol concentrations did not change from baseline (56 ± 16 mg/dL) to 48 weeks of treatment (57 ± 17 mg/dL). However, LDL/HDL ratio decreased significantly (P = 0.036) from 3.4 ± 0.7 to 2.2 ± 0.9, which approached the target level (2.0). During the rosuvastatin treatment period, serum creatine kinase, aldolase, and myoglobin concentrations did not change. In conclusion, rosuvastatin treatment improved serum triglyceride level as well as the LDL/HDL ratio in hyperlipidemic patients with CKD stage 3 and above, without serious adverse effects, suggesting that rosuvastatin is useful to control not only hypercholesterolemia but also hypertriglyceridemia in CKD patients.http://www.sciencedirect.com/science/article/pii/S2211913212006328 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jun Yuto Yosuke Ehara Kazuhiko Shibata Tamio Iwamoto Gen Yasuda Mari Katsumata Yuichiro Yamamoto Nobuhito Hirawa |
spellingShingle |
Jun Yuto Yosuke Ehara Kazuhiko Shibata Tamio Iwamoto Gen Yasuda Mari Katsumata Yuichiro Yamamoto Nobuhito Hirawa SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVE Kidney Research and Clinical Practice |
author_facet |
Jun Yuto Yosuke Ehara Kazuhiko Shibata Tamio Iwamoto Gen Yasuda Mari Katsumata Yuichiro Yamamoto Nobuhito Hirawa |
author_sort |
Jun Yuto |
title |
SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVE |
title_short |
SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVE |
title_full |
SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVE |
title_fullStr |
SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVE |
title_full_unstemmed |
SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVE |
title_sort |
safety and efficacy of rosuvastatin for hyperlipidemia in patients with chronic kidney disease (ckd) stage 3 and above |
publisher |
The Korean Society of Nephrology |
series |
Kidney Research and Clinical Practice |
issn |
2211-9132 |
publishDate |
2012-06-01 |
description |
The frequency of hypertriglyceridemia is high in CKD patients, but few medications are available for controlling this lipid parameter when renal insufficiency advances. We evaluated the safety and efficacy of long-term treatment with rosuvastatin, one of the strong statins for hypercholesterolemic control, on lipid abnormalities in patients with CKD stage 3 and above. The protocol consisted of a 4-week run-in period and a 48-week treatment phase with rosuvastatin. Inclusion criteria were CKD stage 3 and above with serum low-density lipoprotein (LDL) cholesterol levels above 100 mg/dL and triglyceride levels above 150 mg/dL. Patients received 2.5 to 5.0 mg rosuvastatin daily. Lipid parameters and myolysis-related indicators were measured. Forty-nine patients (29 men and 20 women aged 61 ± 9 years, serum creatinine levels above 1.5 mg/dL) were enrolled in the study. Rosuvastatin significantly decreased (P〈0.05) serum LDL cholesterol from 163 ± 39 to 126 ± 31 mg/dL and apolipoprotein B from 151 ± 36 to 108 ± 24 mg/dL at 4 weeks and maintained these parameters at low levels. Rosuvastatin also significantly decreased (P = 0.001) serum triglyceride levels from 194 ± 43 mg/dL at baseline to 160 ± 51 mg/dL at 48 weeks. High-density lipoprotein (HDL) cholesterol concentrations did not change from baseline (56 ± 16 mg/dL) to 48 weeks of treatment (57 ± 17 mg/dL). However, LDL/HDL ratio decreased significantly (P = 0.036) from 3.4 ± 0.7 to 2.2 ± 0.9, which approached the target level (2.0). During the rosuvastatin treatment period, serum creatine kinase, aldolase, and myoglobin concentrations did not change. In conclusion, rosuvastatin treatment improved serum triglyceride level as well as the LDL/HDL ratio in hyperlipidemic patients with CKD stage 3 and above, without serious adverse effects, suggesting that rosuvastatin is useful to control not only hypercholesterolemia but also hypertriglyceridemia in CKD patients. |
url |
http://www.sciencedirect.com/science/article/pii/S2211913212006328 |
work_keys_str_mv |
AT junyuto safetyandefficacyofrosuvastatinforhyperlipidemiainpatientswithchronickidneydiseaseckdstage3andabove AT yosukeehara safetyandefficacyofrosuvastatinforhyperlipidemiainpatientswithchronickidneydiseaseckdstage3andabove AT kazuhikoshibata safetyandefficacyofrosuvastatinforhyperlipidemiainpatientswithchronickidneydiseaseckdstage3andabove AT tamioiwamoto safetyandefficacyofrosuvastatinforhyperlipidemiainpatientswithchronickidneydiseaseckdstage3andabove AT genyasuda safetyandefficacyofrosuvastatinforhyperlipidemiainpatientswithchronickidneydiseaseckdstage3andabove AT marikatsumata safetyandefficacyofrosuvastatinforhyperlipidemiainpatientswithchronickidneydiseaseckdstage3andabove AT yuichiroyamamoto safetyandefficacyofrosuvastatinforhyperlipidemiainpatientswithchronickidneydiseaseckdstage3andabove AT nobuhitohirawa safetyandefficacyofrosuvastatinforhyperlipidemiainpatientswithchronickidneydiseaseckdstage3andabove |
_version_ |
1716756439552229376 |